| 87.49 0.31 (0.36%) | 10-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 106.28 | 1-year : | 124.14 |
| Resists | First : | 91 | Second : | 106.28 |
| Pivot price | 86.38 |
|||
| Supports | First : | 82.7 | Second : | 77.58 |
| MAs | MA(5) : | 87.24  |
MA(20) : | 86.35 |
| MA(100) : | 82.7 |
MA(250) : | 87.98 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 56.6 |
D(3) : | 56.9 |
| RSI | RSI(14): 58.6 |
|||
| 52-week | High : | 106.48 | Low : | 73.3 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MRK ] has closed below upper band by 30.7%. Bollinger Bands are 25.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 88.1 - 88.54 | 88.54 - 88.98 |
| Low: | 86.07 - 86.53 | 86.53 - 86.99 |
| Close: | 86.76 - 87.48 | 87.48 - 88.2 |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Fri, 24 Oct 2025
Merck Q3 Earnings Preview: Issues That Will Dominate The Agenda (NYSE:MRK) - Seeking Alpha
Fri, 24 Oct 2025
Trump cuts IVF drug deal with Merck in exchange for tariff exemption - The Cancer Letter
Wed, 22 Oct 2025
Complaint filed against Merck pharmaceutical company, alleging the Flint River Plant caused brain cancer of two Albany sisters - WALB
Wed, 22 Oct 2025
Merck KGaA to mothball operations at Ireland API plant by end of 2028 - Fierce Pharma
Wed, 22 Oct 2025
Merck (MRK): Valuation Perspective as Groundbreaking Cancer Trial Wins Drive New Investor Focus - Yahoo Finance
Tue, 21 Oct 2025
Analyst Says He’s Buying Merck (MRK) as ‘Market Turns Towards Quality’ - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,500 (M) |
| Shares Float | 2,490 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 80.7 (%) |
| Shares Short | 25,170 (K) |
| Shares Short P.Month | 23,830 (K) |
| EPS | 6.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.56 |
| Profit Margin | 25.7 % |
| Operating Margin | 37.4 % |
| Return on Assets (ttm) | 13 % |
| Return on Equity (ttm) | 35.4 % |
| Qtrly Rev. Growth | -1.9 % |
| Gross Profit (p.s.) | 19.7 |
| Sales Per Share | 25.44 |
| EBITDA (p.s.) | 11.33 |
| Qtrly Earnings Growth | -17.8 % |
| Operating Cash Flow | 18,530 (M) |
| Levered Free Cash Flow | 15,560 (M) |
| PE Ratio | 13.48 |
| PEG Ratio | 0 |
| Price to Book value | 4.47 |
| Price to Sales | 3.43 |
| Price to Cash Flow | 11.8 |
| Dividend | 0.81 |
| Forward Dividend | 0 |
| Dividend Yield | 0.9% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|